881
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.

          Related collections

          Author and article information

          Journal
          New England Journal of Medicine
          N Engl J Med
          Massachusetts Medical Society
          0028-4793
          1533-4406
          November 26 2015
          November 26 2015
          : 373
          : 22
          : 2117-2128
          Article
          10.1056/NEJMoa1504720
          26378978
          91b8b913-e5cf-4e85-b5b7-6bf657504179
          © 2015
          History

          Comments

          Comment on this article

          Related Documents Log
          scite_

          Similar content2,310

          Cited by4,419